Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients
{{output}}
Recently, oncolytic virus (OV) therapy has shown great promise in treating malignancies. However, intravenous safety and inherent lack of immunity are two significant limitations in clinical practice. Herein, we successfully developed a recombinant Newcastle d... ...